Archive: October 2017
Colorectal Cancer
What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer?
Anthony F. Shields, MD, PhD
H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]
Drug Development
Direct-to-Consumer Advertising of Cancer Treatments
Lowell E. Schnipper, MD
H&O What have studies shown about direct-to-consumer advertising of medical treatments? LS A few studies have evaluated direct-to-consumer advertising of medical treatments, but they are […]
Lung Cancer in Focus
How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver
Mark A. Socinski, MD
Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]
Hematology
Current Challenges in the Management of Essential Thrombocythemia
Ariel Kleman, MD, Arun K. Singavi, MD, and Laura C. Michaelis, MD
Abstract: Essential thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms, a category that also includes polycythemia vera and primary myelofibrosis. […]
Prostate Cancer
Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer
Michael T. Schweizer, MD, and Emmanuel S. Antonarakis, MD
Abstract: Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations […]
Myeloma
When to Initiate Treatment in Smoldering Multiple Myeloma
María-Victoria Mateos, MD, PhD
H&O How is smoldering multiple myeloma defined? MM Smoldering multiple myeloma is a plasma cell disorder defined by the presence of a serum monoclonal component […]
Melanoma
In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma
Keith Flaherty, MD
H&O What makes the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib a good combination for use in BRAF-mutated melanoma? KF Like other combinations of […]
Prostate Cancer
The Role of Genomics in Patients With Advanced Prostate Cancer
Maha H. Hussain, MD
H&O What are the main technologic advances that have spurred on the current interest in genomics? MH The current interest in genomics was a downstream […]
Hem/Onc News
Hem/Onc News
Devon Schuyler
First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric antigen […]
Letter From the Editor
Letter from the Editor: How to Treat Hodgkin Lymphoma
Brad S. Kahl, MD
Last weekend, I attended the 2017 ASH Meeting on Hematologic Malignancies. This is an incredible 2-day meeting organized around a series of “How I Treat” […]